Molecular Response Opens Access to Genomic DNA for Research
21.05.12
SAN DIEGO, Apr 18, 2012 (BUSINESS WIRE) --
Molecular Response (MRL), a privately held molecular diagnostic services
company and a leader in identification of target populations for high
value therapeutics, today announced the availability of genomic DNA from
the world's largest bank of viable cryopreserved tumor cells.
Genomic DNA is a key component to understanding cancer, a disease
characterized by DNA sequence abnormalities. Genomic DNA from these
tumors can be used for sequencing, mutation and SNP detection,
population mutation frequency analysis, and copy number determination.
The large bank of specimens available at Molecular Response will greatly
reduce the amount of time spent by researchers in locating significant
sets of specimens to use in studies.
The genomic DNA available at Molecular Response is isolated from over
12,000 individual tumors, representing over 60 different cancer
indications, collected from a de-identified US population over the last
20 years. With cryopreserved tumor cells as the source of DNA, Molecular
Response offers quality genomic DNA that has not been subjected to the
adverse effects of formalin fixation. Additionally, since the tumors
have been disaggregated, the genomic DNA is representative of the entire
sample, correcting for intratumor heterogeneity. Each specimen is
annotated by cancer indication, gender, age, collection site, clinical
diagnosis, histology, and pathology review.
Source: MarketWatch (press release)